Xenitra Announces A$12 Million Three-Year Pharmaceutical Offtake Deal with China’s Kangsheng

Xenitra’s Three-Pillar Growth Approach and OTC Pharmaceuticals Market Entry

Xenitra Limited’s growth strategy is built on three complementary revenue streams: OTC pharmaceuticals, nutritional products, and the OPAL tokenized real-world-asset sales platform. Recent months have seen progress in the OTC pharmaceuticals pillar through regulatory groundwork, supply-chain development, wholesale pharmaceutical distribution licensing, and acquiring Fukang, a Hong Kong-based pharmaceutical trading company. The Kangsheng agreement signifies a pivotal shift from market preparation to substantial commercial execution.

Non-Executive Chairman Dr Anthony Noble stated this partnership fulfills the company’s third and final growth pillar, transitioning all business units from concept to execution in 2026. The nutritionals segment is supported by a A$30 million annual partnership with Rockcheck, while the OPAL tokenization platform has experienced rapid high-margin sales growth. The OTC pharmaceuticals division’s commercial launch completes Xenitra’s three-pillar platform.

Kangsheng’s Market Leadership and Distribution Scale in China

Kangsheng Hong Kong International Trading Limited is a licensed pharmaceutical sales and marketing leader with a robust distribution infrastructure across China. Operating an omnichannel network spanning e-commerce and retail pharmacies, Kangsheng generates over RMB 900 million (approx. A$190 million) in annual revenue. This established network offers Xenitra immediate access to a high-velocity distribution channel, bypassing years of organic growth.

The partnership provides Xenitra with a ready market route in one of the world’s largest healthcare consumption markets, supported by structural drivers such as an aging population, increased health awareness, and sustained demand for quality-assured imported health products via cross-border channels. Kangsheng’s scale and decision to partner with Xenitra validate the company’s sourcing and distribution capabilities.

Agreement Details and Procurement Commitments

The three-year cooperation agreement between Fukang and Kangsheng, effective July 2026 to July 2029, covers pharmaceutical supply, channel development, operational support, and long-term market expansion across China and the Asia-Pacific. Kangsheng commits to purchasing a minimum of A$12 million (or USD equivalent) in pharmaceutical and health products over the term. Orders will be processed quarterly and annually, providing structured procurement visibility. The agreement may extend beyond three years, subject to 30 days’ written termination notice.

The procurement focuses on globally compliant prescription and OTC medicines plus broader health products, emphasizing Australian, European, and other international sources. Fukang is prioritized as Kangsheng’s core pharmaceutical supplier but Kangsheng may source from alternatives if Fukang lacks stock, valid qualifications, or if pricing is uncompetitive, ensuring commercial flexibility.

Payment Terms and Commercial Rollout Timeline

The agreement outlines staged payments balancing Kangsheng’s cash flow and Fukang’s working capital: 20% deposit upon order confirmation, 30% at dispatch, and 50% within three working days after receipt, inspection, and documentation verification. This aligns with standard pharmaceutical trading practices and mitigates supply chain risk.

Operational onboarding is expected to complete this quarter, enabling initial commercial orders soon. Foundational work—regulatory licensing, subsidiary acquisition, and partner agreement—has been finalized, setting the stage for significant commercial activity. Investors will monitor the timing and scale of initial orders as indicators of revenue realization.

Distribution-Centric Model and Asia-Pacific Expansion Plans

The Kangsheng deal integrates into Xenitra’s broader distribution-led ecosystem across China, combining e-commerce, livestream commerce, and distributor infrastructure to onboard international and domestic brands at scale. This agreement is a strategic element of a comprehensive market access platform designed to distribute leading international OTC pharmaceutical brands rapidly through a high-velocity network.

Xenitra aims to expand its FMCG and healthcare footprint across the Asia-Pacific by introducing established international brands to these markets. The Kangsheng partnership is viewed as a foundational step toward deeper strategic collaborations and replication with other distributors in neighboring Asian countries, offering scalable pathways for international brand entry.

Regulatory and Licensing Foundations for OTC Pharmaceutical Operations

Xenitra has systematically developed its OTC pharmaceuticals pillar through regulatory approvals and supply-chain establishment, including securing wholesale pharmaceutical distribution licenses—a prerequisite for regulated markets—and acquiring Fukang. This positions the company for compliant operations within China’s healthcare distribution framework. The Kangsheng agreement builds upon these regulatory and operational foundations, transitioning from licensing to active commercial supply.

Compliance with China’s stringent pharmaceutical import regulations is critical. By securing licenses and acquiring an established Hong Kong-based trading entity, Xenitra has mitigated regulatory risks. The agreement is governed by both PRC Civil Code and Hong Kong commercial law, reflecting the cross-border nature of the Fukang-Kangsheng partnership.

OTC Pharmaceuticals in Relation to Nutritionals Partnership

Xenitra’s OTC pharmaceuticals division complements its established nutritionals business, underpinned by a A$30 million per annum partnership with Rockcheck. While both target China’s growing healthcare market, they operate in distinct product categories and distribution channels.

This portfolio approach diversifies Xenitra’s healthcare distribution across multiple revenue streams. Management highlights that all three pillars now generate live commercial activity, offering shareholders multiple concurrent value creation avenues beyond development stages.

OPAL Tokenized Real-World-Asset Platform Growth

The OPAL real-world-asset tokenized sales ecosystem forms Xenitra’s third growth pillar. Management reports rapid high-margin sales growth since launch, indicating parallel advancement of all three strategic pillars. OTC pharmaceuticals are now commercially active alongside nutritionals and OPAL tokenization, generating simultaneous revenue across diverse business lines.

This concurrent activation within 2026 marks a major operational milestone, accelerating revenue generation and shortening the gap between investment and returns. Investors will likely track revenue contributions and growth rates across OPAL, nutritionals, and OTC pharmaceuticals.

Market Dynamics and Structural Growth Drivers in China’s Healthcare Sector

China’s healthcare consumption market benefits from strong structural tailwinds: an aging population, rising health consciousness, and sustained demand for imported health products from developed markets like Australia and Europe. These trends favor international pharmaceutical suppliers accessing Chinese consumers through established distribution partnerships.

The Kangsheng collaboration positions Xenitra to capitalize on these drivers by facilitating efficient entry of international brands into China’s market. Consumer preference for quality-assured cross-border health products further enhances growth prospects during the agreement’s term.

Supply Relationship Flexibility and Contingencies

While Fukang is Kangsheng’s priority pharmaceutical supplier, the agreement includes flexibility allowing Kangsheng to source from others if Fukang lacks stock, valid product qualifications, or if pricing is uncompetitive. These provisions ensure supply continuity and commercial realism.

This mature agreement structure balances exclusivity with practical supply chain needs, safeguarding Kangsheng’s supply security while maintaining Fukang’s competitive advantage. Investors should note actual purchases from Fukang may be below the A$12 million minimum if alternative sourcing occurs.